175 related articles for article (PubMed ID: 7851498)
1. Identification of a region of the human endothelin ETA receptor required for interaction with bosentan.
Adachi M; Furuichi Y; Miyamoto C
Eur J Pharmacol; 1994 Oct; 269(2):225-34. PubMed ID: 7851498
[TBL] [Abstract][Full Text] [Related]
2. Identification of specific regions of the human endothelin-B receptor required for high affinity binding with endothelin-3.
Adachi M; Furuichi Y; Miyamoto C
Biochim Biophys Acta; 1994 Sep; 1223(2):202-8. PubMed ID: 8086489
[TBL] [Abstract][Full Text] [Related]
3. Identification of a domain of ETA receptor required for ligand binding.
Adachi M; Yang YY; Trzeciak A; Furuichi Y; Miyamoto C
FEBS Lett; 1992 Oct; 311(2):179-83. PubMed ID: 1397307
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist.
Clozel M; Breu V; Gray GA; Kalina B; Löffler BM; Burri K; Cassal JM; Hirth G; Müller M; Neidhart W
J Pharmacol Exp Ther; 1994 Jul; 270(1):228-35. PubMed ID: 8035319
[TBL] [Abstract][Full Text] [Related]
5. Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels.
Seo B; Oemar BS; Siebenmann R; von Segesser L; Lüscher TF
Circulation; 1994 Mar; 89(3):1203-8. PubMed ID: 8124808
[TBL] [Abstract][Full Text] [Related]
6. Characterization of three non-peptide endothelin receptor ligands using human cloned ETA and ETB receptors.
Buchan KW; Alldus C; Christodoulou C; Clark KL; Dykes CW; Sumner MJ; Wallace DM; White DG; Watts IS
Br J Pharmacol; 1994 Aug; 112(4):1251-7. PubMed ID: 7952888
[TBL] [Abstract][Full Text] [Related]
7. The effect of bosentan, a new potent endothelin receptor antagonist, on the pathogenesis of cerebral vasospasm.
Shigeno T; Clozel M; Sakai S; Saito A; Goto K
Neurosurgery; 1995 Jul; 37(1):87-90; discussion 90-1. PubMed ID: 8587696
[TBL] [Abstract][Full Text] [Related]
8. Effects of Ro 47-0203 and PD155080 on the plasma kinetics, receptor binding and vascular effects of endothelin in the pig.
Hemsén A; Modin A; Wanecek M; Malmström RE; Weitzberg E
Eur J Pharmacol; 1996 Dec; 318(2-3):369-76. PubMed ID: 9016927
[TBL] [Abstract][Full Text] [Related]
9. Identification of a ligand-binding site of the human endothelin-A receptor and specific regions required for ligand selectivity.
Adachi M; Furuichi Y; Miyamoto C
Eur J Biochem; 1994 Feb; 220(1):37-43. PubMed ID: 8119297
[TBL] [Abstract][Full Text] [Related]
10. Endothelin B receptor-mediated vasoconstriction induced by endothelin A receptor antagonist.
Zhang Y; Oliver JR; Horowitz JD
Cardiovasc Res; 1998 Sep; 39(3):665-73. PubMed ID: 9861310
[TBL] [Abstract][Full Text] [Related]
11. Effect of BQ-123 and Ro 47-0203 (bosentan) on endothelin-induced vasoconstriction in the rat skin.
Lawrence E; Brain SD
Eur J Pharmacol; 1994 Jul; 260(1):103-6. PubMed ID: 7957619
[TBL] [Abstract][Full Text] [Related]
12. Separable binding sites for the natural agonist endothelin-1 and the non-peptide antagonist bosentan on human endothelin-A receptors.
Breu V; Hashido K; Broger C; Miyamoto C; Furuichi Y; Hayes A; Kalina B; Löffler BM; Ramuz H; Clozel M
Eur J Biochem; 1995 Jul; 231(1):266-70. PubMed ID: 7628480
[TBL] [Abstract][Full Text] [Related]
13. Dipeptide sulfonamides as endothelin ETA/ETB receptor antagonists.
Ksander GM; Shetty SS; DelGrande D; Balwierczak JL; Bruseo CW; Savage P; deJesus R; Yuan A; Webb RL; Jeng AY
Can J Physiol Pharmacol; 2002 May; 80(5):464-9. PubMed ID: 12056554
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological inactivation of the endothelin type A receptor in the early chick embryo: a model of mispatterning of the branchial arch derivatives.
Kempf H; Linares C; Corvol P; Gasc JM
Development; 1998 Dec; 125(24):4931-41. PubMed ID: 9811577
[TBL] [Abstract][Full Text] [Related]
15. Mutational analysis of human endothelin receptors ETA and ETB identification of regions involved in the selectivity for endothelin 3 or cyclo-(D-Trp-D-Asp-Pro-D-Val-Leu).
Becker A; Haendler B; Hechler U; Schleuning WD
Eur J Biochem; 1994 May; 221(3):951-8. PubMed ID: 8181477
[TBL] [Abstract][Full Text] [Related]
16. Ligand binding domain of the human endothelin-B subtype receptor.
Wada K; Hashido K; Terashima H; Adachi M; Fujii Y; Hiraoka O; Furuichi Y; Miyamoto C
Protein Expr Purif; 1995 Jun; 6(3):228-36. PubMed ID: 7663155
[TBL] [Abstract][Full Text] [Related]
17. Distinct subdomains of human endothelin receptors determine their selectivity to endothelinA-selective antagonist and endothelinB-selective agonists.
Sakamoto A; Yanagisawa M; Sawamura T; Enoki T; Ohtani T; Sakurai T; Nakao K; Toyo-oka T; Masaki T
J Biol Chem; 1993 Apr; 268(12):8547-53. PubMed ID: 8473300
[TBL] [Abstract][Full Text] [Related]
18. Receptor- and non-receptor-mediated clearance of big-endothelin and endothelin-1: differential effects of acute and chronic ETA receptor blockade.
Burkhardt M; Barton M; Shaw SG
J Hypertens; 2000 Mar; 18(3):273-9. PubMed ID: 10726713
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of a novel non-peptide endothelin receptor antagonist (bosentan) in rat liver and vasculature.
Phillips PA; Risvanis J; Aldred K; Burrell LM; Bartholomeusz B
Clin Sci (Lond); 1995 Dec; 89(6):575-9. PubMed ID: 8549075
[TBL] [Abstract][Full Text] [Related]
20. Aspartate mutation distinguishes ETA but not ETB receptor subtype-selective ligand binding while abolishing phospholipase C activation in both receptors.
Rose PM; Krystek SR; Patel PS; Liu EC; Lynch JS; Lach DA; Fisher SM; Webb ML
FEBS Lett; 1995 Mar; 361(2-3):243-9. PubMed ID: 7698331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
